カテゴリ： GlobalData, アメリカ, 企業調査

Immune Pharmaceuticals Inc (IMNP)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Immune Pharmaceuticals Inc (IMNP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C8234
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：72
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Immune Pharmaceuticals Inc (Immune Pharma), formerly EpiCept Corp is a drug development company that develops novel therapies for immunologic and inflammatory diseases. The company’s pipeline products include Bertilimumab and Nanocyclo. Its Bertilimumab is a human monoclonal antibody designed to block the protein eotaxin-1 which causes various diseases. Immune Pharma’s Nanocyclo is a nanoformulation of cyclosporine which enables the molecule to penetrate into the skin layers and provide local anti-inflammatory effect. The company also provides Crolibulin and Azixa, a novel small molecule vascular disrupting agent developed for the treatment of patients with solid tumors, primary brain cancers and metastatic tumors. Its products are used to treat bullous pemphigoid, ulcerative colitis, atopic dermatitis, psoriasis, and other inflammatory conditions. Immune Pharma develops drugs in the areas of immuno-oncology, nano-dermatology and neuropathic pain. The company has operations in the US and Israel. Immune Pharma is headquartered in Englewood Cliffs, New Jersey, the US.

Immune Pharmaceuticals Inc (IMNP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Immune Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 14
Partnerships 14
WuXi Biologics and Immune Pharma Enter into Co-Development Agreement 14
Immune Pharma Enters into Agreement with STC Biologics 15
Immune Pharma Plans to Partner with Hebrew University of Jerusalem 16
Immune Pharma Enters Into Co-Development Agreement With Yeda Research 17
Licensing Agreements 18
Immune Pharmaceuticals Enters into Licensing Agreement with Pint Pharma 18
SATT Sud Est Enters into Licensing Agreement with Immune Pharma 19
Maxim Pharma Enters into Licensing Agreement with Immune Pharma 20
Novel Pain Therapeutics Amends Option for Licensing Agreement with Immune Pharma 21
Immune Pharma Enters into Licensing Agreement with BioNanoSim 22
Immune Pharma Enters into Licensing Agreement with Yissum 23
Immune Pharma to Enter into Licensing Agreement with Yissum Research Development 25
Lonza Sales Enters into Licensing Agreement with Immune Pharma for Bertilimumab 26
Equity Offering 27
Immune Pharma Raises USD18 Million in Public Offering of Units 27
Immune Pharma Plans to Raise up to USD2.5 Million in Public Offering of Shares 29
Immune Pharma to Spin-off its Cytovia 30
Immune Pharma Plans to Raise up to USD3 Million in Public Offering of Shares 31
Immune Pharma Raises USD2 Million in Share Purchase Plan 32
Maxim Pharma to Raise upto USD20 Million in Private Placement of Shares 33
Immune Pharma Completes Spin Off of Pain and Neurology Business 34
Immune Pharma Raises USD1 Million in Private Placement of Shares 35
Immune Pharma Raises USD0.8 Million in Private Placement of Shares 36
Immune Pharma Raises USD1 Million in Private Placement of Shares 37
Immune Pharmaceuticals Raises USD9 Million in Private Placement of Series D Redeemable Convertible Preferred Stock 38
Immune Pharma Completes Underwriters Exercise of Partial Over-Allotment Option of Public Offering of Units for USD9.7 Million 40
Immune Pharma Raises USD1 Million in Private Placement of Units 41
Immune Pharma Raises USD11.7 Million in Private Placement of Units and Warrants 42
Debt Offering 43
Immune Pharma Raises USD1.5 Million in First Tanche of Private Placement of Debentures 43
Immune Pharma Raises USD0.5 Million in Private Placment of 6% Notes Due 2018 44
Immune Pharma Raises USD1 Million in Private Placement of Convertible Notes 45
Acquisition 46
Immune Pharma Completes Acquisition Of EpiCept In Reverse Takeover Transaction 46
Immune Pharmaceuticals Inc – Key Competitors 48
Immune Pharmaceuticals Inc – Key Employees 49
Immune Pharmaceuticals Inc – Locations And Subsidiaries 50
Head Office 50
Other Locations & Subsidiaries 50
Recent Developments 51
Strategy And Business Planning 51
Jul 19, 2017: Immune Pharmaceuticals Provides Update on Plan to Implement a Spin-off of Cytovia into a Separate Publicly Traded Oncology Company 51
Financial Announcements 52
Apr 02, 2018: Immune Pharmaceuticals Announces 2017 Financial Results 52
Nov 15, 2017: Immune Pharmaceuticals Announces Third Quarter 2017 Financial Results and Provides a Corporate Update 54
Aug 28, 2017: Immune Pharmaceuticals Provides Business Update and Summary of Recent Financial Highlights 56
Corporate Communications 57
Nov 27, 2017: Immune Provides Update Regarding NASDAQ US Listing and Departure of Officer 57
Aug 29, 2017: Immune Pharmaceuticals Receives NASDAQ Letter 58
Aug 14, 2017: Immune Pharmaceuticals Appoints Tony Fiorino, MD, PhD as Chief Medical Officer and Chief Operating Officer 59
Jun 19, 2017: Immune Receives NASDAQ Compliance Letter 60
May 26, 2017: Immune Receives Nasdaq Letters 61
Apr 24, 2017: Immune Receives Nasdaq Letter 62
Mar 13, 2017: Immune Pharmaceuticals Granted Additional Time to Comply with Nasdaq Listing Requirement 63
Jan 27, 2017: Immune Pharmaceuticals Appoints New Chairman of the Board of Directors 64
Government and Public Interest 65
Apr 24, 2017: Immune Pharmaceuticals Announces Corporate Restructuring 65
Other Significant Developments 66
Feb 20, 2018: Immune Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders and Provides Business Update 66
Aug 04, 2017: Immune Pharmaceuticals Issues Letter to Shareholders 69
Appendix 72
Methodology 72
About GlobalData 72
Contact Us 72
Disclaimer 72

List of Tables
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Immune Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 10
Immune Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
WuXi Biologics and Immune Pharma Enter into Co-Development Agreement 14
Immune Pharma Enters into Agreement with STC Biologics 15
Immune Pharma Plans to Partner with Hebrew University of Jerusalem 16
Immune Pharma Enters Into Co-Development Agreement With Yeda Research 17
Immune Pharmaceuticals Enters into Licensing Agreement with Pint Pharma 18
SATT Sud Est Enters into Licensing Agreement with Immune Pharma 19
Maxim Pharma Enters into Licensing Agreement with Immune Pharma 20
Novel Pain Therapeutics Amends Option for Licensing Agreement with Immune Pharma 21
Immune Pharma Enters into Licensing Agreement with BioNanoSim 22
Immune Pharma Enters into Licensing Agreement with Yissum 23
Immune Pharma to Enter into Licensing Agreement with Yissum Research Development 25
Lonza Sales Enters into Licensing Agreement with Immune Pharma for Bertilimumab 26
Immune Pharma Raises USD18 Million in Public Offering of Units 27
Immune Pharma Plans to Raise up to USD2.5 Million in Public Offering of Shares 29
Immune Pharma to Spin-off its Cytovia 30
Immune Pharma Plans to Raise up to USD3 Million in Public Offering of Shares 31
Immune Pharma Raises USD2 Million in Share Purchase Plan 32
Maxim Pharma to Raise upto USD20 Million in Private Placement of Shares 33
Immune Pharma Completes Spin Off of Pain and Neurology Business 34
Immune Pharma Raises USD1 Million in Private Placement of Shares 35
Immune Pharma Raises USD0.8 Million in Private Placement of Shares 36
Immune Pharma Raises USD1 Million in Private Placement of Shares 37
Immune Pharmaceuticals Raises USD9 Million in Private Placement of Series D Redeemable Convertible Preferred Stock 38
Immune Pharma Completes Underwriters Exercise of Partial Over-Allotment Option of Public Offering of Units for USD9.7 Million 40
Immune Pharma Raises USD1 Million in Private Placement of Units 41
Immune Pharma Raises USD11.7 Million in Private Placement of Units and Warrants 42
Immune Pharma Raises USD1.5 Million in First Tanche of Private Placement of Debentures 43
Immune Pharma Raises USD0.5 Million in Private Placment of 6% Notes Due 2018 44
Immune Pharma Raises USD1 Million in Private Placement of Convertible Notes 45
Immune Pharma Completes Acquisition Of EpiCept In Reverse Takeover Transaction 46
Immune Pharmaceuticals Inc, Key Competitors 48
Immune Pharmaceuticals Inc, Key Employees 49
Immune Pharmaceuticals Inc, Other Locations 50
Immune Pharmaceuticals Inc, Subsidiaries 50

List of Figures
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Immune Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[Immune Pharmaceuticals Inc (IMNP)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Abbott Point of Care Inc：企業の製品パイプライン分析2018
    Summary Abbott Point of Care Inc (Abbott Point), a subsidiary of Abbott Laboratories, is a medical device company that offers diagnostic products. The company manufactures, develops, and distributes medical diagnostic and data management products for in-vitro diagnostic and healthcare markets. Its p …
  • Novaliq GmbH-製薬・医療分野：企業M&A・提携分析
    Summary Novaliq GmbH (Novaliq) is a drug delivery company that develops pharmaceutical formulations. The company develops novel ophthalmic and dermatological products, and solutions for organ preservation based on the physicochemical properties of semifluorinated alkanes. It offers NovaTears, a pres …
  • Asian Hotels (North) Limited：企業の戦略・SWOT・財務情報
    Asian Hotels (North) Limited - Strategy, SWOT and Corporate Finance Report Summary Asian Hotels (North) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Aggreko Plc (AGK)：企業の財務・戦略的SWOT分析
    Aggreko Plc (AGK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • JenaValve Technology Inc：医療機器：M&Aディール及び事業提携情報
    Summary JenaValve Technology Inc (JenaValve Technology), a subsidiary of JenaValve Technology GmbH, is a medical device company that develops and manufactures transcatheter aortic valve replacement (TAVR) systems for transapical and transfemoral implantation. The company’s TAVR system is an investig …
  • Wallenstam AB (WALL B)：企業の財務・戦略的SWOT分析
    Summary Wallenstam AB (Wallenstam) is a construction company that offers building and property management solutions. The company's services include commercial and residential properties development, housing programs, property investment and management, urban development, property ownership services, …
  • Republic National Distributing Co：企業の戦略・SWOT・財務情報
    Republic National Distributing Co - Strategy, SWOT and Corporate Finance Report Summary Republic National Distributing Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • John Wood Group Plc (WG.)：石油・ガス：M&Aディール及び事業提携情報
    Summary John Wood Group Plc (Wood) is a provider of project, engineering and technical services. The company offers comprehensive solutions that improve the performance of customers' industrial assets across the asset life cycle. Its services span from concept to decommissioning and include asset so …
  • Konica Minolta, Inc. (4902)-医療機器分野：企業M&A・提携分析
    Summary Konica Minolta, Inc. (Konica Minolta) develops, manufactures and sells printing systems and solutions for production print professionals. The company’s product portfolio includes multi-functional peripherals (MFPs), printers, equipment for production print systems and graphic arts, equipment …
  • Parsons Corp (PSN)：企業の財務・戦略的SWOT分析
    Parsons Corp (PSN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Australian Mines Limited：企業の戦略・SWOT・財務分析
    Australian Mines Limited - Strategy, SWOT and Corporate Finance Report Summary Australian Mines Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Landsvirkjun hf-エネルギー分野：企業M&A・提携分析
    Summary Landsvirkjun hf (Landsvirkjun) is a state-owned energy utility that conducts the generation and transmission of electricity in Iceland. It generates electricity through several renewable sources such as hydro, geothermal, and wind. Through subsidiaries, the company also offers telecommunicat …
  • Eisai Co Ltd (4523)：製薬・医療：M&Aディール及び事業提携情報
    Summary Eisai Co Ltd (Eisai) is a pharmaceutical company that undertakes the research, development, manufacture and marketing of pharmaceuticals, including over-the-counter (OTC) drugs, prescription medicines and generics. The company’s franchise areas in research include neurology and oncology. Eis …
  • PTT Public Company Limited：企業の戦略・SWOT・財務分析
    PTT Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary PTT Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Sc Arcada Con Srl：企業の戦略的SWOT分析
    Sc Arcada Con Srl - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Aspyrian Therapeutics Inc-製薬・医療分野：企業M&A・提携分析
    Summary Aspyrian Therapeutics Inc (Aspyrian Therapeutics) is a biotechnology company which develops precision targeted medicines to handle both the primary tumor and systemic disease. Its lead pipeline product, RM-1929, is under development for the treatment of different cancer types, including canc …
  • Invenergy LLC：電力：M&Aディール及び事業提携情報
    Summary Invenergy LLC (Invenergy) is a full-service energy solutions provider. It invests, develops, constructs, owns, and operates renewable and other clean energy generation and storage facilities. The company captures, generates, and stores power from wind, solar, natural gas, and energy storage …
  • Proteus Digital Health Inc：企業の戦略的SWOT分析
    Proteus Digital Health Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • ToolGen Inc-製薬・医療分野：企業M&A・提携分析
    Summary ToolGen Inc (ToolGen) is a genome editing company that concentrates on translating the genetic knowledge into transformative products for biomedicine and agriculture. The company creates intellectual property rights for essential tools and technologies for editing the genetic information in …
  • Tejas Networks Ltd (TEJASNET)：企業の財務・戦略的SWOT分析
    Tejas Networks Ltd (TEJASNET) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆